Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model

Nature Communications

Volumn 5, Issue , 2014, Pages

  Lozovaya, N ^a,b,c   Gataullina, S ^a,b,c   Tsintsadze, T ^a,b   Tsintsadze, V ^a,b   Pallesi Pocachard, E ^a,b   Minlebaev, M ^a,b,d   Goriounova, N A ^a,b   Buhler, E ^a,b   Watrin, F ^a,b   Shityakov, S ^e   Becker, A J ^f   Bordey, A ^g   Milh, M ^h   Scavarda, D ^h   Bulteau, C ^c,i   Dorfmuller, G ^c,i   Delalande, O ⁱ   Represa, A ^a,b   Cardoso, C ^a,b   Dulac, O ^c,i,j   Ben Ari, Y ^a,b   Burnashev, N ^a,b   more..

^a Turing Center for Living Systems CENTURI Aix Marseille University   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSERM   (France)

^d KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h TIMONE HOSPITAL   (France)

ⁱ FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^j HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; DQP 1105; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2C; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RAPAMYCIN; TETRODOTOXIN; TUBERIN; UBP 141; UNCLASSIFIED DRUG; 4-(5-(4-BROMOPHENYL)-3-(6-METHYL-2-OXO-4-PHENYL-1,2-DIHYDROQUINOLIN-3-YL)-4,5-DIHYDRO-1H-PYRAZOL-1-YL)-4-OXOBUTANOIC ACID; ANTICONVULSIVE AGENT; MTOR PROTEIN, MOUSE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2C NMDA RECEPTOR; PYRAZOLE DERIVATIVE; QUINOLONE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

DISEASE INCIDENCE; GENE EXPRESSION; GRANULAR MEDIUM; HETEROZYGOSITY;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; AUTOMATISM; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN ELECTROPHYSIOLOGY; BRAIN SLICE; BRAIN TISSUE; CAUCASIAN; CONTROLLED STUDY; CORTICAL DYSPLASIA; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTOGENESIS; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; FETUS; GENE EXPRESSION; GENE REPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNEURON; INTRACTABLE EPILEPSY; MALE; MOUSE; MURINE MODEL; NEOCORTEX; NERVE CELL; NONHUMAN; PERINATAL PERIOD; PHENOTYPE; POWER SPECTRUM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSORY STIMULATION; SINGLE DRUG DOSE; SOMATOSENSORY CORTEX; SPIKE WAVE; STELLATE CELL; SURGICAL PATIENT; SYNAPTIC TRANSMISSION; TEMPORAL SUMMATION; TONIC CLONIC SEIZURE; TREMOR; TUBEROUS SCLEROSIS; UPREGULATION; VOLTAGE CLAMP TECHNIQUE; WAVELET ANALYSIS; WHOLE CELL PATCH CLAMP; ACTION POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROTOMY; PATCH CLAMP TECHNIQUE; PATHOLOGY; SIGNAL TRANSDUCTION; TISSUE CULTURE TECHNIQUE; TRANSGENIC MOUSE;

ACTION POTENTIALS; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; GENE EXPRESSION REGULATION; HETEROZYGOTE; HUMANS; MALE; MICE; MICE, TRANSGENIC; MICROTOMY; NEOCORTEX; PATCH-CLAMP TECHNIQUES; PYRAZOLES; QUINOLONES; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; TISSUE CULTURE TECHNIQUES; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84905453328     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5563     Document Type: Article

References (70)

1. Curatolo, P. in Sclerosis Complex From Basic Science To Clinical Phenotypes (I.C.N. AssociationMac Keith Press, 2003
2. Zeng, L. H., Xu, L., Gutmann, D. H. & Wong, M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 63, 444-453 (2008 (Pubitemid 351614710)
3. Meikle, L. et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 28, 5422-5432 (2008
4. Ehninger, D. et al. Reversal of learning deficits in a Tsc2+/-mouse model of tuberous sclerosis. Nat. Med. 14, 843-848 (2008
5. Curatolo, P., Bombardieri, R. & Jozwiak, S. Tuberous sclerosis. Lancet 372, 657-668 (2008
6. Henske, E. P. et al. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am. J. Pathol. 151, 1639-1647 (1997 (Pubitemid 27527926)
7. Qin, W. et al. Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events. Brain Pathol. 20, 1096-1105 (2010
8. Crino, P. B., Aronica, E., Baltuch, G. & Nathanson, K. L. Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 74, 1716-1723 (2010
9. Curatolo, P., Bombardieri, R. & Cerminara, C. Current management for epilepsy in tuberous sclerosis complex. Curr. Opin. Neurol. 19, 119-123 (2006
10. Jansen, F. E., Van Huffelen, A. C., Algra, A. & Van Nieuwenhuizen, O. Epilepsy surgery in tuberous sclerosis: A systematic review. Epilepsia 48, 1477-1484 (2007 (Pubitemid 47245804)
11. Wu, W. E. et al. Brain MR spectroscopic abnormalities in ?MRI-negative' tuberous sclerosis complex patients. Epilepsy Behav. 27, 319-325 (2013
12. Major, P. et al. Are cortical tubers epileptogenic? Evidence from electrocorticography. Epilepsia 50, 147-154 (2009
13. Kaufmann, R., Kornreich, L. & Goldberg-Stern, H. Unusual clinical presentation of tuberless tuberous sclerosis complex. J. Child. Neurol. 24, 361-364 (2009
14. Cusmai, R., Chiron, C., Curatolo, P., Dulac, O. & Tran-Dinh, S. Topographic comparative study of magnetic resonance imaging and electroencephalography in 34 children with tuberous sclerosis. Epilepsia 31, 747-755 (1990
15. Feliciano, D. M., Su, T., Lopez, J., Platel, J. C. & Bordey, A. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J. Clin. Invest. 121, 1596-1607 (2011
16. Meikle, L. et al. A mouse model of tuberous sclerosis: Neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci. 27, 5546-5558 (2007 (Pubitemid 350021088)
17. Uhlmann, E. J. et al. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann. Neurol. 52, 285-296 (2002 (Pubitemid 35001494)
18. Way, S. W. et al. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum. Mol. Genet. 18, 1252-1265 (2009
19. Chevere-Torres, I., Maki, J. M., Santini, E. & Klann, E. Impaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberin. Neurobiol. Dis. 45, 156-164 (2011
20. Goorden, S. M., Van Woerden, G. M., Van Der Weerd, L., Cheadle, J. P. & Elgersma, Y. Cognitive deficits in Tsc1+/-mice in the absence of cerebral lesions and seizures. Ann. Neurol. 62, 648-655 (2007
21. Bateup, H. S. et al. Excitatory/Inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron 78, 510-522 (2013
22. Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J. & Sabatini, B. L. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat. Neurosci. 8, 1727-1734 (2005 (Pubitemid 41683201)
23. Zilles, K., Qu, M. S., Kohling, R. & Speckmann, E. J. Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: Quantitative in vitro receptor autoradiography. Neuroscience 94, 1051-1061 (1999 (Pubitemid 29509672)
24. White, R. et al. Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers. Ann. Neurol. 49, 67-78 (2001 (Pubitemid 32163007)
25. Talos, D. M., Kwiatkowski, D. J., Cordero, K., Black, P. M. & Jensen, F. E. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann. Neurol. 63, 454-465 (2008 (Pubitemid 351614711)
26. Crino, P. B., Duhaime, A. C., Baltuch, G. & White, R. Differential expression of glutamate and GABA-A receptor subunit mRNA in cortical dysplasia. Neurology 56, 906-913 (2001 (Pubitemid 32293585)
27. Feldmeyer, D. Excitatory neuronal connectivity in the barrel cortex. Front. Neuroanat. 6, 24 (2012
28. Beierlein, M., Fall, C. P., Rinzel, J. & Yuste, R. Thalamocortical bursts trigger recurrent activity in neocortical networks: Layer 4 as a frequency-dependent gate. J. Neurosci. 22, 9885-9894 (2002 (Pubitemid 35332873)
29. Feldmeyer, D., Egger, V., Lubke, J. & Sakmann, B. Reliable synaptic connections between pairs of excitatory layer 4 neurones within a single ?barrel' of developing rat somatosensory cortex. J. Physiol. 521(Pt 1): 169-190 (1999
30. Binshtok, A. M., Fleidervish, I. A., Sprengel, R. & Gutnick, M. J. NMDA receptors in layer 4 spiny stellate cells of the mouse barrel cortex contain the NR2C subunit. J. Neurosci. 26, 708-715 (2006 (Pubitemid 43237135)
31. Fleidervish, I. A., Binshtok, A. M. & Gutnick, M. J. Functionally distinct NMDA receptors mediate horizontal connectivity within layer 4 of mouse barrel cortex. Neuron 21, 1055-1065 (1998 (Pubitemid 29018075)
32. Lefort, S., Tomm, C., Floyd Sarria, J. C. & Petersen, C. C. The excitatory neuronal network of the C2 barrel column in mouse primary somatosensory cortex. Neuron 61, 301-316 (2009
33. Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B. & Seeburg, P. H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12, 529-540 (1994 (Pubitemid 24100885)
34. Costa, B. M. et al. N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: Preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse. J. Pharmacol. Exp. Ther. 331, 618-626 (2009
35. Acker, T. M. et al. Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol. Pharmacol. 80, 782-795 (2011
36. Ichikawa, T. et al. A case of solitary subependymal giant cell astrocytoma: Two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism. J. Mol. Diagn. 7, 544-549 (2005 (Pubitemid 41479721)
37. Hakami, T. et al. NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness. PLoS ONE 4, e6755 (2009
38. Baybis, M. et al. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann. Neurol. 56, 478-487 (2004 (Pubitemid 39319337)
39. Becker, A. J. et al. Focal cortical dysplasia of Taylor's balloon cell type: Mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis. Ann. Neurol. 52, 29-37 (2002 (Pubitemid 34693740)
40. Ljungberg, M. C. et al. Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann. Neurol. 60, 420-429 (2006 (Pubitemid 44684978)
41. Miyata, H., Chiang, A. C. & Vinters, H. V. Insulin signaling pathways in cortical dysplasia and TSC-tubers: Tissue microarray analysis. Ann. Neurol. 56, 510-519 (2004 (Pubitemid 39319341)
42. Wong, M. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations. Exp. Neurol. 244, 22-26 (2013
43. Fisher, R. S. et al. Epileptic seizures and epilepsy: Definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46, 470-472 (2005 (Pubitemid 40470667)
44. Nie, D. et al. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat. Neurosci. 13, 163-172 (2010
45. Sato, A. et al. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat. Commun. 3, 1292 (2012
46. Vail, E. A., Rakowski, S. K., Numis, A. L. & Thiele, E. A. Role of mutational analysis in diagnosis of tuberous sclerosis complex. Clin. Genet. 75, 282-285 (2009
47. Chu-Shore, C. J., Major, P., Camposano, S., Muzykewicz, D. & Thiele, E. A. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 51, 1236-1241 (2010
48. Beenhakker, M. P. & Huguenard, J. R. Neurons that fire together also conspire together: Is normal sleep circuitry hijacked to generate epilepsy? Neuron 62, 612-632 (2009
49. Huguenard, J. R. & McCormick, D. A. Thalamic synchrony and dynamic regulation of global forebrain oscillations. Trends Neurosci. 30, 350-356 (2007 (Pubitemid 46991122)
50. McCormick, D. A. & Bal, T. Sleep and arousal: Thalamocortical mechanisms. Annu. Rev. Neurosci. 20, 185-215 (1997 (Pubitemid 27106380)
51. Kandel, A. & Buzsaki, G. Cellular-synaptic generation of sleep spindles, spike-and-wave discharges, and evoked thalamocortical responses in the neocortex of the rat. J. Neurosci. 17, 6783-6797 (1997 (Pubitemid 27366629)
52. Traub, R. D. et al. A possible role for gap junctions in generation of very fast EEG oscillations preceding the onset of, and perhaps initiating, seizures. Epilepsia 42, 153-170 (2001 (Pubitemid 32204795)
53. Lachaux, J. P. et al. The many faces of the gamma band response to complex visual stimuli. Neuroimage 25, 491-501 (2005
54. Moddel, G. et al. The NMDA receptor NR2B subunit contributes to epileptogenesis in human cortical dysplasia. Brain. Res. 1046, 10-23 (2005 (Pubitemid 40775869)
55. Najm, I. M. et al. Epileptogenicity correlated with increased N-methyl-Daspartate receptor subunit NR2A/B in human focal cortical dysplasia. Epilepsia 41, 971-976 (2000 (Pubitemid 30640861)
56. Ghasemi, M. & Schachter, S. C. The NMDA receptor complex as a therapeutic target in epilepsy: A review. Epilepsy Behav. 22, 617-640 (2011
57. Liu, Y. et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 27, 2846-2857 (2007 (Pubitemid 46438991)
58. Krystal, J. H., Anand, A. & Moghaddam, B. Effects of NMDA receptor antagonists: Implications for the pathophysiology of schizophrenia. Arch. Gen. Psychiatry 59, 663-664 (2002 (Pubitemid 34747249)
59. Carlen, M. et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol. Psychiatry 17, 537-548 (2012
60. Cepeda, C., Andre, V. M., Vinters, H. V., Levine, M. S. & Mathern, G. W. Are cytomegalic neurons and balloon cells generators of epileptic activity in pediatric cortical dysplasia? Epilepsia 46(Suppl 5): 82-88 (2005 (Pubitemid 40962126)
61. Aronica, E., Boer, K., Baybis, M., Yu, J. & Crino, P. Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly. Acta Neuropathol. 114, 287-293 (2007 (Pubitemid 47226155)
62. Samadani, U., Judkins, A. R., Akpalu, A., Aronica, E. & Crino, P. B. Differential cellular gene expression in ganglioglioma. Epilepsia 48, 646-653 (2007 (Pubitemid 46587612)
63. Wong, M. & Crino, P. B. in mTOR and Epileptogenesis in Developmental Brain Malformations 4th edn (eds Noebels, J.L., Avoli, M., Rogawski, M.A., Olsen, R.W. & Delgado-Escueta, A.V.) (National Center for Biotechnology Information, 2012
64. Crino, P. B. Focal brain malformations: A spectrum of disorders along the mTOR cascade. Novartis Found. Symp. 288, 260-272 discussion 272-81 (2007
65. Dayas, C. V., Smith, D. W. & Dunkley, P. R. An emerging role for the Mammalian target of rapamycin in ?pathological' protein translation: Relevance to cocaine addiction. Front. Pharmacol. 3, 13 (2012
66. Han, J. M. & Sahin, M. TSC1/TSC2 signaling in the CNS. FEBS Lett. 585, 973-980 (2011
67. Landis, S. C. et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490, 187-191 (2012
68. Clark, D. E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88, 815-821 (1999 (Pubitemid 29398551)
69. Cruciani, G., Pastor, M. & Guba, W. VolSurf: A new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. 11(Suppl 2): S29-S39 (2000
70. Dedrick, R. L. & Flessner, M. F. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J. Natl. Cancer. Inst. 89, 480-487 (1997). (Pubitemid 27147264)